• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Announces FDA Has Completed Review of Bovaer®, First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry

    5/28/24 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    • Food and Drug Administration confirms Bovaer meets safety and efficacy requirements
    • Elanco expects product launch and added carbon credit value to producers beginning in the third quarter
    • Elanco announces agreement with dsm-firmenich to expand distribution of Bovaer across North America, adding both the Canada and Mexico markets

    GREENFIELD, Ind., May 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its comprehensive, multi-year review of Bovaer® (3-NOP), a first-in-class methane-reducing feed ingredient, and determined the product meets safety and efficacy requirements for use in lactating dairy cattle.

    Feeding one tablespoon of Bovaer per lactating dairy cow per day can reduce methane emissions about 30%.

    "This monumental announcement has the ability to accelerate the opportunity for climate-neutral dairy farming while creating a new revenue stream for dairy farmers across the country," said Jeff Simmons, President and CEO, Elanco Animal Health. "We appreciate FDA's commitment to maintaining high standards for science-based review, while balancing the need to quickly bring solutions to the market. Bovaer represents another example of Elanco being a partner of choice in animal health, where the capabilities of our talented R&D, regulatory and commercial teams are delivering significant value.

    Simmons continued: "As global temperatures breach new thresholds, consumers demand more sustainable products and the farm economy battles profitability challenges, we are excited to bring Bovaer to the market as a potential solution. Bovaer will create value for farmers, while helping food companies meet consumer demands and deliver on their sustainability commitments. As animal, human and now environmental health continue to converge, Bovaer is one of the most significant innovations that considers this intersection and provides consumers, farmers and society what they want for our future."

    Bovaer represents another blockbuster potential innovation in Elanco's portfolio and further accelerates livestock sustainability, the next billion-dollar plus market in animal health. This innovation is expected to accelerate market development and increase innovation in this space.

    Bovaer works by suppressing the enzyme in the cow's rumen that forms methane. Feeding one tablespoon of Bovaer per lactating dairy cow per day can reduce methane emissions about 30% or about 1.2 metric tons of carbon dioxide equivalent (CO2e) emissions annually, while creating opportunity for dairy farmers to be financially rewarded for reducing their dairy's carbon footprint.i Feeding one million cows Bovaer would reduce emissions equivalent to removing more than 285,000 cars from the road for a year.ii Feeding Bovaer to cattle has proven to be safe for animals, producers and consumers.

    Expanding Access Across North America 

    Elanco and dsm-firmenich have agreed to expand Elanco's commercialization of Bovaer across North America. In addition to the U.S., Elanco will also now have the right to market Bovaer in Canada and Mexico, where the product is already available for use in beef and dairy cattle. This expanded agreement can accelerate the opportunity to make climate-neutral cattle farming in North America a reality this decade.

    "We congratulate Elanco and the U.S. dairy sector, on this important milestone, and will support Elanco by providing initial supplies from Europe," said Dimitri de Vreeze, CEO at dsm-firmenich. "This strategic collaboration exemplifies how we can accelerate the expansion and adoption of Bovaer in North America to significantly decrease methane emissions on a large scale, and thereby support global efforts to combat climate change. Bovaer holds the key to a transformative shift in the global dairy sector, and launching this feed ingredient in the U.S. after years of dedicated research, trials, and industry collaboration is a testament to its global potential."

    Simmons said, "We appreciate the work dsm-firmenich has invested in this revolutionary product and are pleased they've recognized Elanco as the global farm animal health leader and the right partner to bring this solution to farmers across North America."

    Why Methane Matters

    This announcement comes at a pivotal time. According to the United Nations, the world's population has until the year 2030 to curb greenhouse gas emissions (GHG) or deal with irreversible impacts to the planet.iii In response, about two-thirds of all Fortune 500 companies have set significant climate commitment goals.iv Reducing enteric methane emissions from cattle—naturally generated through the enteric fermentation process—represents a key opportunity. Methane lasts about a decade in the atmosphere and is 27x more potent than carbon dioxide at trapping heat—so smaller reductions create greater impact on temperature.v By mitigating methane, the livestock industry can reduce the rate of climate warming and allow food companies and retailers to make meaningful progress toward their Scope 3 emissions goals.

    "Reducing enteric methane is critical if we are to reach our climate goals," said Dr. Frank Mitloehner, CLEAR Center Director and University California Davis Professor and Cooperative Extension Air Quality Specialist. "It's exciting our farmers will have an important tool to do that, in Bovaer."

    Creating New Revenue Streams for Farmers

    Feeding Bovaer to cows provides a scalable and credible way for dairy farmers to benefit from being good stewards of the environment by being financially rewarded for implementing on-farm sustainability interventions.

    "At an added cost of a few cents a gallon of milk, Bovaer can help food companies meet their climate commitments and consumer desire for more sustainable dairy products," said Katie Cook, Vice President, Livestock Sustainability and Farm Animal Marketing at Elanco. "Meanwhile, by engaging in voluntary carbon markets and securing USDA and state conservation programming, dairy producers have a scalable sustainability practice with the potential to create an annual return of $20 or more per lactating cow by feeding Bovaervi. Our goal is to make this opportunity a reality starting this summer, while creating a self-sustaining carbon inset market for American agriculture."

    Dairy farmers incorporate Bovaer into their rations and quantify the effect using carbon market-friendly tools like UpLook™ by Elanco, an insights-based engine designed to quantify greenhouse gas emissions reductions. The tool utilizes on-farm data and peer-reviewed science to identify key drivers of an operation's carbon footprint and track the progress of sustainability efforts. UpLook connects seamlessly to Athian, the first-of-its-kind livestock carbon inset marketplace. This seamless process allows farmers to quantify their emissions reduction efforts and certify carbon credits for sale. In addition to the carbon marketplace, the U.S. Department of Agriculture has awarded $89 million in funding to support farms using technologies like Bovaer to reduce their methane emissions.vii

    "Products like Elanco's Bovaer will allow U.S. farmers to be rewarded for participating in voluntary, producer-led sustainability efforts," said Gregg Doud, President and CEO, National Milk Producers Federation. "Consumers around the world are demanding lower-carbon foods. Bovaer is an innovation that can help U.S. dairy farmers remain globally competitive and maintain their role as leaders in more sustainable dairy production."

    Greg Bethard, a dairy farmer from Kansas who has used UpLook to quantify his greenhouse gas emissions, expressed his excitement around today's announcement.

    "Dairy producers have made great strides improving the sustainability of our operations," said Bethard, High Plains Ponderosa Dairy. "Today's announcement provides access to a product that has been extensively studied and shown to reduce emissions from dairy cows. Bovaer is a value-creation opportunity for dairies—it's about helping us provide product in a manner most of our consumers are wanting—a lower carbon footprint food."

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.

    The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions.

    Bovaer is a trademark of dsm-firmenich. Elanco is a trademark of Elanco or its affiliates. © 2024 Elanco or its affiliates.


    i Kebreab, E., Bannink, A., Pressman, E. M., Walker, N., Karagiannis, A., van Gastelen, S., & Dijkstra, J. (2023). A meta-analysis of effects of 3-nitrooxypropanol on methane production, yield, and intensity in dairy cattle. Journal of Dairy Science, 106(2), 927–936.

     https://doi.org/10.3168/jds.2022-22211 based on 60 ppm, 25 kg/d DMI, 30% NDF, and 305 day lactation results in a 31.6% or 1.2 MT reduction

    ii Greenhouse Gas Equivalencies Calculator | US EPA

    iii Transforming our world: the 2030 Agenda for Sustainable Development | Department of Economic and Social Affairs

    (un.org) at https://sustainabledevelopment.un.org/content/documents/21252030%20Agenda%20for%20Sustainable%20Development%20web.pdf

    iv Commitment issues: Markers of real climate action in the Fortune Global 500. 2023. Climate Impact Partners. Available at: https://www.climateimpact.com/news-insights/fortune-global-500-climate-commitments/

    v Intergovernmental Panel on Climate Change Sixth Assessment Report https://www.ipcc.ch/report/ar6/wg1/

    vi Assumes 1.2 mt of CO2e/cow/year abated, cumulative value of at least $170/mt of Co2 from USDA incentive plus carbon inset market value less product and other administrative fees

    vii Regional Conservation Partnership Program 2023 Awarded Projects | Natural Resources Conservation Service (usda.gov)

    Media Contact: Season Solorio (765) 316-0233 [email protected]

    Investor Contact: Kathryn Grissom (317) 273-9284 [email protected]

    Feeding Bovaer to cows provides a scalable and credible way for dairy farmers to benefit from being good stewards of the environment by being financially rewarded for implementing on-farm sustainability interventions.

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-announces-fda-has-completed-review-of-bovaer-first-in-class-methane-reducing-feed-ingredient-for-us-dairy-industry-302156287.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    More analyst ratings

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*

    Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dogAdjustable collar fits comfortably and securely on a dog of any sizeStrengthens Elanco's 25-year Advantage brand familyAvailable at pet specialty, dollar, grocery and mass retailers, with a suggested retail price below $25**INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the launch of its Advantage™ Collar for Dogs, a new product providing long-lasting protection against two parasites that don't take a season off – fleas and ticks. Designed for dogs and puppies 12 weeks of age and older, this dog collar kills and repels fl

    4/9/26 8:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Participate in Upcoming Investor Conferences

    INDIANAPOLIS, Ind., Feb. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, February 26, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the BofA 2026 Animal Health Summit at 11:35 a.m. ET.On Monday, March 2, Bob VanHimbergen, executive vice president and CFO, and Luke Smith, vice president and CFO – US Pet Health, US Farm Animal, and Global Manufacturing, will participate in a fireside

    2/19/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    4/7/26 5:19:22 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    4/7/26 5:18:50 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    4/7/26 5:18:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    4/9/26 1:42:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Elanco Animal Health Incorporated

    DEFA14A - Elanco Animal Health Inc (0001739104) (Filer)

    4/8/26 10:14:07 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Elanco Animal Health Incorporated

    DEF 14A - Elanco Animal Health Inc (0001739104) (Filer)

    4/8/26 10:07:35 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

    INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-

    1/22/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms

    12/9/25 7:40:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care